Ziprasidone in Huntington's disease: the first case reports
Ziprasidone in Huntington's disease: the first case reports
复制标题
DOI：
10.1177/0269881103174009
复制
发表时间：
2003-12-01
影响因子：
4.1
通讯作者：
Kapfhammer, HP
中科院分区：
文献类型：
--
作者：
Bonelli, RM;Mayr, BM;Kapfhammer, HP
Huntington's disease (HD) is a relentlessly progressive neuropsychiatric disorder with an underlying autosomal dominantly inherited genetic defect. Classical antipsychotics (i.e. phenothiazines or butyrophenones) are the most used medication to reduce the (probably dopamine-born) choreiform hyperkinesias. Ziprasidone is the latest of a new class of atypical antipsychotics; it has not been studied so far in this indication. We report three genetically confirmed HD patients who improved significantly in several categories of the motor scale of the Unified HD Rating Scale.
